Utility of FDG PET/CT in Non-Prostate Male Genitourinary Pathology

Harry W. Schroeder III, MD, PhD; Bruce Barron, MD, MHA, FACNM

doi:10.36255/molecular-imaging-of-non-prostate-male-genitourinary-pathology

PDF HTML XML

Published: Nov 8, 2023

DOI: https://doi.org/10.36255/molecular-imaging-of-non-prostate-male-genitourinary-pathology

Keywords:

FDG PET/CT, non-prostate male genitourinary pathology, penile cancer, seminal vesicle cancer, testicular cancer

Harry W. Schroeder III, MD, PhD

Department of Radiology and Imaging Sciences, Emory University, Atlanta, GA, USA

Bruce Barron, MD, MHA, FACNM

Department of Radiology and Imaging Sciences, Emory University, Atlanta, GA, USA

ABSTRACT

Much has been written about the utility of FDG PET/CT (fluorodeoxyglucose positron emission tomography/computed tomography) in frequently encountered malignancies such as lung cancer, breast cancer, and gastrointestinal cancers. Although less common, FDG PET/CT can be a useful modality in the evaluation and staging of cancers of the male GU (genitourinary) tract. Similar to its application with the more common malignancies, FDG PET/CT can provide helpful information when evaluating for sites of disease such as recurrent, nodal, and/or metastatic disease in the setting of these GU cancers. This chapter reviews the utility of PET/CT in the evaluation of non-prostate male GU pathologies such as the penis and testicles. Some very rare tumors as well as infectious and/or inflammatory conditions that can affect the GU system are also described.